Granted Patent
B2
US 12,630,624 · App. 17/714,942 · Granted May 19, 2026
Anti-IL-27 antibodies and uses thereof
Inventors:
Jonathan Hill (Salem, MA); Scott Chappel (Milton, MA); Michael Gladstone (Cambridge, MA); Bianka Prinz (Lebanon, NH); Andrew Lake (Westwood, MA); Christine Miller (Amesbury, MA); Kerry White (Danvers, MA); Jing Hua (Wellesley, MA); Pamela M. Holland (Belmont, MA); Matthew Rausch (Cambridge, MA); Devapregasan Moodley (Cambridge, MA)
Assignee:
SURFACE ONCOLOGY, LLC
C07K16/244A61K39/3955A61P35/00G01N33/6869A61K2039/505A61K45/06C07K2317/56C07K2317/76C07K2317/92G01N2333/54
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure relates to anti-IL-27 antibodies, and antigen-binding portions thereof. The disclosure also relates to methods for treating or ameliorating one or more symptoms of a disease, such as cancer, by administering the antibodies or antigen-binding portion thereof. The disclosure also relates to methods for detecting IL-27 in, for example, a subject or a sample.
Claims (14)
1 . A method of treating an interleukin 27 (IL-27)-expressing cancer in a subject, the method comprising administering to the subject an effective amount of an isolated monoclonal antibody that specifically binds to and antagonizes human IL-27, or antigen binding portion thereof, wherein the antibody or antigen binding portion thereof comprises:
heavy chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 161, 162 and 163, respectively, and light chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 169, 170 and 171, respectively; or
heavy chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 164, 165, and 166, respectively, and light chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 172, 173, and 174, respectively.
2 . The method of claim 1 , wherein the antibody or antigen binding portion thereof comprises the heavy chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 161, 162 and 163, respectively, and the light chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 169, 170 and 171, respectively.
3 . The method of claim 2 , wherein the IL-27-expressing cancer is selected from the group consisting of renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), lung cancer, Hodgkin's disease, sarcoma, testicular cancer, ovarian cancer, pancreas cancer, breast cancer, melanoma, head and neck cancer, colorectal cancer, bladder cancer, endometrial cancer, prostate cancer, thyroid cancer, gastroesophageal cancer, gastric cancer, brain cancer, lymphoma, and leukemia.
4 . The method of claim 2 , wherein the isolated monoclonal antibody, or antigen binding portion thereof, is administered in combination with one or more additional therapeutic agents or procedures.
5 . The method of claim 4 , wherein the one or more additional therapeutic agents or procedures is selected from the group consisting of a chemotherapy; a cytokine; a surgical procedure; a radiation procedure; and a combination thereof.
6 . The method of claim 2 , wherein the isolated monoclonal antibody or antigen binding portion thereof comprises a heavy chain variable region comprising SEQ ID NO: 167 and a light chain variable region comprising SEQ ID NO: 175.
7 . The method of claim 2 , wherein the isolated monoclonal antibody or antigen binding portion thereof comprises a heavy chain comprising SEQ ID NO: 181 and a light chain comprising SEQ ID NO: 179, or the isolated monoclonal antibody or antigen binding portion thereof comprises a heavy chain comprising SEQ ID NO: 177 and a light chain comprising SEQ ID NO: 179.
8 . The method of claim 4 , wherein the one or more additional therapeutic agents is selected from the group consisting of: PDR001, nivolumab, pembrolizumab, pidilizumab, MEDI0680, REGN2810, TSR-042, PF-06801591, and AMP-224.
9 . The method of claim 4 , wherein the one or more additional therapeutic agents is selected from the group consisting of: FAZ053, Atezolizumab, Avelumab, Durvalumab, and BMS-936559.
10 . The method of claim 4 , wherein the one or more additional therapeutic is selected from the group agents consisting of sunitinib, cabozantinib, axitinib, lenvatinib, everolimus, bevacizumab, epacadostat, NKTR-214, tivozanib, abexinostat, pilimumab, tremelimumab, pazopanib, sorafenib, temsirolimus, ramucirumab, niraparib, savolitinib, vorolanib, regorafenib, donafenib, camrelizumab, pexastimogene, devacirepvec, ramucirumab, apatinib, encapsulated doxorubicin, tivantinib, ADI-PEG 20, binimetinib, apatinib mesylate, nintedanib, lirilumab, nivolumab, pembrolizumab, atezolizumab, avelumab, durvalumab, cemiplimab, tislelizumab, and spartalizumab.
11 . The method of claim 4 , wherein the one or more additional therapeutic agents is a TIM-3 inhibitor, wherein the TIM-3 inhibitor is MGB453 or TSR-022.
12 . The method of claim 4 , wherein the one or more additional therapeutic agents is a LAG-3 inhibitor, wherein the LAG-3 inhibitor is selected from the groups consisting of LAAG525, BMS-986016, and TSR-033.
Assignments (6)
SECURITY INTEREST
Recorded Aug 14, 2026
From: COHERUS ONCOLOGY, INC.; SURFACE ONCOLOGY, LLC
To: INNOVATUS LIFE SCIENCES LENDING FUND I, LP
Reel/Frame 075661/0837 →
SECURITY INTEREST
Recorded May 8, 2024
From: COHERUS BIOSCIENCES, INC.; COHERUS INTERMEDIATE CORP.; INTEKRIN THERAPEUTICS INC.; SURFACE ONCOLOGY, LLC; COHERUS ONCOLOGY SUPPORTIVE CARE LLC
To: ANKURA TRUST COMPANY, LLC
Reel/Frame 067348/0160 →
MERGER AND CHANGE OF NAME
Recorded Oct 23, 2023
From: SURFACE ONCOLOGY, INC.; CRIMSON MERGER SUB II, LLC
To: SURFACE ONCOLOGY, LLC
Reel/Frame 065311/0520 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 6, 2023
From: HILL, JONATHAN; CHAPPEL, SCOTT; GLADSTONE, MICHAEL; LAKE, ANDREW; MILLER, CHRISTINE; WHITE, KERRY; HUA, JING; HOLLAND, PAMELA M.
To: SURFACE ONCOLOGY, INC.
Reel/Frame 063238/0685 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 6, 2023
From: PRINZ, BIANKA
To: ADIMAB LLC
Reel/Frame 063238/0702 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 30, 2023
From: ADIMAB, LLC
To: SURFACE ONCOLOGY, INC.
Reel/Frame 063176/0094 →
Continuity (3)
Provisional Application
62646496
· Mar 22, 2018
References Cited (353)
US 3710795A
· Higuchi et al.
· 1973
[cited by applicant]
US 3773919A
· Boswell et al.
· 1973
[cited by applicant]
US 4676980A
· Segal et al.
· 1987
[cited by applicant]
US 4863457A
· Lee
· 1989
[cited by applicant]
US 5223409A
· Ladner et al.
· 1993
[cited by applicant]
US 5403484A
· Ladner et al.
· 1995
[cited by applicant]
US 5427908A
· Dower et al.
· 1995
[cited by applicant]
US 5501856A
· Ohtori et al.
· 1996
[cited by applicant]
US 5516637A
· Huang et al.
· 1996
[cited by applicant]
US 5571698A
· Ladner et al.
· 1996
[cited by applicant]
US 5580717A
· Dower et al.
· 1996
[cited by applicant]
US 5595756A
· Bally
· 1997
[cited by examiner]
US 5624821A
· Winter et al.
· 1997
[cited by applicant]
US 5648260A
· Winter et al.
· 1997
[cited by applicant]
US 5658727A
· Barbas et al.
· 1997
[cited by applicant]
US 5698426A
· Huse
· 1997
[cited by applicant]
US 5733743A
· Johnson et al.
· 1998
[cited by applicant]
US 5750753A
· Kimae et al.
· 1998
[cited by applicant]
US 5780225A
· Wigler et al.
· 1998
[cited by applicant]
US 5821047A
· Garrard et al.
· 1998
[cited by applicant]
US 5969108A
· Mccafferty et al.
· 1999
[cited by applicant]
US 6001329A
· Buchsbaum et al.
· 1999
[cited by applicant]
US 6005079A
· Casterman et al.
· 1999
[cited by applicant]
US 6194551B1
· Idusogie et al.
· 2001
[cited by applicant]
US 6300064B1
· Knappik et al.
· 2001
[cited by applicant]
US 6933368B2
· Co et al.
· 2005
[cited by applicant]
US 6995259B1
· Vargeese et al.
· 2006
[cited by applicant]
US 7148330B2
· Timans et al.
· 2006
[cited by applicant]
US 7595048B2
· Honjo et al.
· 2009
[cited by applicant]
US 7612181B2
· Wu et al.
· 2009
[cited by applicant]
US 7943743B2
· Korman et al.
· 2011
[cited by applicant]
US 8008449B2
· Korman et al.
· 2011
[cited by applicant]
US 8258268B2
· Wu et al.
· 2012
[cited by applicant]
US 8354509B2
· Carven et al.
· 2013
[cited by applicant]
US 8691953B2
· Timans et al.
· 2014
[cited by applicant]
US 8728474B2
· Honjo et al.
· 2014
[cited by applicant]
US 8779105B2
· Korman et al.
· 2014
[cited by applicant]
US 8784807B2
· Vignali et al.
· 2014
[cited by applicant]
US 8900587B2
· Carven et al.
· 2014
[cited by applicant]
US 8952136B2
· Carven et al.
· 2015
[cited by applicant]
US 9067999B1
· Honjo et al.
· 2015
[cited by applicant]
US 9073994B2
· Honjo et al.
· 2015
[cited by applicant]
US 9181349B2
· Baurin et al.
· 2015
[cited by applicant]
US 9221917B2
· Baurin et al.
· 2015
[cited by applicant]
US 9518113B2
· Vignali et al.
· 2016
[cited by applicant]
US 9913879B2
· Hunter et al.
· 2018
[cited by applicant]
US 20030008343A1
· Timans et al.
· 2003
[cited by applicant]
US 20030054407A1
· Luo
· 2003
[cited by applicant]
US 20050214296A1
· Kastelein et al.
· 2005
[cited by applicant]
US 20060019303A1
· Castle et al.
· 2006
[cited by applicant]
US 20080124345A1
· Rothe et al.
· 2008
[cited by applicant]
US 20080241223A1
· Nivaggioli et al.
· 2008
[cited by applicant]
US 20090074793A1
· Martin et al.
· 2009
[cited by applicant]
US 20090220498A1
· Finotto
· 2009
[cited by applicant]
US 20100008917A1
· Hosken et al.
· 2010
[cited by applicant]
US 20100092465A1
· Hosken et al.
· 2010
[cited by applicant]
US 20100297127A1
· Ghilardi et al.
· 2010
[cited by applicant]
US 20100303777A1
· Creus et al.
· 2010
[cited by applicant]
US 20110110852A1
· Miller et al.
· 2011
[cited by applicant]
US 20110189203A1
· Hermans et al.
· 2011
[cited by applicant]
US 20120039840A1
· Hunter et al.
· 2012
[cited by applicant]
US 20120183548A1
· Wong et al.
· 2012
[cited by applicant]
US 20120189578A1
· Collison et al.
· 2012
[cited by applicant]
US 20120195900A1
· Ghayur et al.
· 2012
[cited by applicant]
US 20120201746A1
· Liu et al.
· 2012
[cited by applicant]
US 20120225030A1
· Malefyt et al.
· 2012
[cited by applicant]
US 20120251541A1
· Baurin et al.
· 2012
[cited by applicant]
US 20120258118A1
· Fox et al.
· 2012
[cited by applicant]
US 20130004416A1
· Wu et al.
· 2013
[cited by applicant]
US 20130189262A1
· Wong et al.
· 2013
[cited by applicant]
US 20140010822A1
· Fox et al.
· 2014
[cited by applicant]
US 20140100359A1
· Wu et al.
· 2014
[cited by applicant]
US 20140170658A1
· Timans et al.
· 2014
[cited by applicant]
US 20140213768A1
· Wu et al.
· 2014
[cited by applicant]
US 20150004167A1
· Wu et al.
· 2015
[cited by applicant]
US 20150284459A1
· Kuchroo et al.
· 2015
[cited by applicant]
US 20150366987A1
· Bodyak et al.
· 2015
[cited by applicant]
US 20160051672A1
· Stewart et al.
· 2016
[cited by applicant]
US 20160200811A1
· Baurin et al.
· 2016
[cited by applicant]
US 20160235827A1
· Wagner et al.
· 2016
[cited by applicant]
US 20170058026A1
· Kuchroo et al.
· 2017
[cited by applicant]
US 20170073410A1
· Vignali et al.
· 2017
[cited by applicant]
US 20170218091A1
· Ambrosi
· 2017
[cited by applicant]
US 20170320967A1
· Yang et al.
· 2017
[cited by applicant]
US 20170340708A1
· Xu et al.
· 2017
[cited by applicant]
US 20180155450A1
· Baurin et al.
· 2018
[cited by applicant]
US 20180194838A1
· Yang et al.
· 2018
[cited by applicant]
US 20180237475A1
· Tagaya et al.
· 2018
[cited by applicant]
US 20180349550A1
· Azimi et al.
· 2018
[cited by applicant]
US 20190106504A1
· Wu et al.
· 2019
[cited by applicant]
US 20190169252A1
· Kim et al.
· 2019
[cited by applicant]
EP 0036676B1
· 1984
[cited by applicant]
EP 0133988A2
· 1985
[cited by applicant]
EP 0058481B1
· 1986
[cited by applicant]
EP 0088046B1
· 1987
[cited by applicant]
EP 0143949B1
· 1988
[cited by applicant]
EP 0488401A1
· 1992
[cited by applicant]
EP 0430539B1
· 1994
[cited by applicant]
EP 1537878B1
· 2010
[cited by applicant]
EP 2161336B1
· 2013
[cited by applicant]
EP 2170959B1
· 2013
[cited by applicant]
EP 2700409A1
· 2014
[cited by applicant]
EP 3003350B1
· 2018
[cited by applicant]
EP 2758513B1
· 2018
[cited by applicant]
EP 3041501B1
· 2019
[cited by applicant]
WO WO9002809A1
· 1990
[cited by applicant]
WO WO9110737A1
· 1991
[cited by applicant]
WO WO9201047A1
· 1992
[cited by applicant]
WO WO9218619A1
· 1992
[cited by applicant]
WO WO9311236A1
· 1993
[cited by applicant]
WO WO9315722A1
· 1993
[cited by applicant]
WO WO9404678A1
· 1994
[cited by applicant]
WO WO9420069A1
· 1994
[cited by applicant]
WO WO9425591A1
· 1994
[cited by applicant]
WO WO9429351A2
· 1994
[cited by applicant]
WO WO9515982A2
· 1995
[cited by applicant]
WO WO9520401A1
· 1995
[cited by applicant]
WO WO9627011A1
· 1996
[cited by applicant]
WO WO9951642A1
· 1999
[cited by applicant]
WO 2005079848A2
· 2005
[cited by applicant]
WO WO2007024715A2
· 2007
[cited by applicant]
WO WO2008024188A2
· 2008
[cited by applicant]
WO 2008135239A1
· 2008
[cited by applicant]
WO WO2009036379A2
· 2009
[cited by applicant]
WO WO2010027827A2
· 2010
[cited by applicant]
WO WO2010077634A1
· 2010
[cited by applicant]
WO WO2010105256A1
· 2010
[cited by applicant]
WO WO2011066342A2
· 2011
[cited by applicant]
WO 2011133931A1
· 2011
[cited by applicant]
WO 2011140151A1
· 2011
[cited by applicant]
WO WO2012009568A2
· 2012
[cited by applicant]
WO 2012135345A1
· 2012
[cited by applicant]
WO WO2013079174A1
· 2013
[cited by applicant]
WO WO2013173223A1
· 2013
[cited by applicant]
WO WO2015103072A1
· 2015
[cited by applicant]
WO WO2016106159A1
· 2016
[cited by applicant]
WO 2017025698A1
· 2017
[cited by applicant]
WO 2017093408A1
· 2017
[cited by applicant]
WO 2017196432A1
· 2017
[cited by applicant]
WO 2018191438A1
· 2018
[cited by applicant]
WO 2019024979A1
· 2019
[cited by applicant]
WO 2019025391A1
· 2019
[cited by applicant]
WO WO2019183499A1
· 2019
[cited by applicant]
WO 2020123011A1
· 2020
[cited by applicant]
Skolnick et al (Trends Biotechnol. Jan. 2000;18(1):34-9) (Year: 2000).
[cited by examiner]
Burgess et al. (J. Cell Biol. 111:2129-2138, 1990) (Year: 1990).
[cited by examiner]
Lazar et al. (Mol. Cell. Biol., 8:1247-1252, 1988) (Year: 1988).
[cited by examiner]
Miosge (Proc Natl Acad Sci U S A. Sep. 15, 2015;112(37):E5189-98) (Year: 2015).
[cited by examiner]
Bork (Genome Research, 2000, 10:398-400) (Year: 2000).
[cited by examiner]
Kulmanov et al.(Bioinformatics, 34(4), 2018, 660-668) (Year: 2018).
[cited by examiner]
Vajdos et al. (J Mol Biol. Jul. 5, 2002;320(2):415-28) (Year: 2002).
[cited by examiner]
Brown et al. (J Immunol. May 1996;156(9):3285-91) (Year: 1996).
[cited by examiner]
Vattekatte, (PeerJ. Mar. 6, 2020:8:e8408. doi: 10.7717/peerj.8408. eCollection 2020.) (Year: 2020).
[cited by examiner]
Edwards et al. (Mol Biol. Nov. 14, 2003;334(1):103-18) (Year: 2003).
[cited by examiner]
Lloyd et al. (Protein Eng Des Sel. Mar. 2009;22(3):159-68. Epub Oct. 29, 2008.) (Year: 2009).
[cited by examiner]
Goel et al. (J Immunol. Dec. 15, 2004;173(12):7358-67) (Year: 2004).
[cited by examiner]
Khan et al. (J Immunol (2014) 192 (11): 5398-5405) (Year: 2014).
[cited by examiner]
Poosarla et al. (Biotechnol Bioeng. Jun. 2017 ; 114(6): 1331-1342) (Year: 2017).
[cited by examiner]
Rabia, et al. (Biochem Eng J. Sep. 15, 2018:137:365-374. Epub Jun. 5, 2018) (Year: 2018).
[cited by examiner]
Aagaard et al (Advanced Drug Delivery Reviews 59 (2007) 75-86) (Year: 2007).
[cited by examiner]
Warzocha et al (Leukemia and Lymphoma (1997) vol. 24. pp. 267-281) (Year: 1997).
[cited by examiner]
McKeague et al (J Nucleic Acids. 2012;2012:748913. Epub Oct. 24, 2012) (Year: 2012).
[cited by examiner]
Guido et al (Curr Med Chem. 2008; 15(1):37-46) (Year: 2008).
[cited by examiner]
Clark et al (J. Med. Chem., 2014, 57 (12), pp. 5023-5038) (Year: 2014).
[cited by examiner]
Sporn et al, “Chemoprevention of Cancer,” Carcinogenesis, vol. 21 (2000), 525-530 (Year: 2000).
[cited by examiner]
Auerbach et al (Cancer and Metastasis Reviews, 2000, 19: 167-172) (Year: 2000).
[cited by examiner]
Gura T (Science, 1997, 278(5340): 1041-1042) (Year: 1997).
[cited by examiner]
HogenEsch et al (J Control Release. Dec. 10, 2012; 164(2): 183-186.) (Year: 2012).
[cited by examiner]
Chaouat, G., et al., “Early Regulators in abortion and implications for a preeclampsia model,” Journal of Reproductive Immunology 82(2):131-140, Elsevier Science Ireland, Ireland (Oct. 2009).
[cited by applicant]
Xu, F., et al., “IL-27 is Elevated in Acute Lung Injury and Mediates Inflammation,” Journal of Clinical Immunology: 1257-1268, Kluwer Academic Publishers, United States (Jul. 2013).
[cited by applicant]
Yoshimoto, T., et al., “Potential Clinical application of interleukin-27 an antitumor agent,” Cancer Science 106(9):1103-1110, Wiley Online Library, United States (Sep. 2015).
[cited by applicant]
Examination Report dated Mar. 21, 2024 issued in corresponding New Zealand Patent Application No. 767839 (4 pages).
[cited by applicant]
Składanowska, K. et al., “Structural basis of activation and antagonism of receptor signaling mediated by interleukin-27”, Cell Reports, vol. 41, Issue 3, pp. 1-13, Oct. 18, 2022 (22 pages).
[cited by applicant]
Office Action dated Oct. 30, 2024, CA Application No. 3093740 (28 pages).
[cited by applicant]
Altschul, S.F., et al., “Basic Local Alignment Search Tool,” Journal of Molecular Biology 215(3):403-410, Elsevier, United Kingdom (Oct. 1990).
[cited by applicant]
Altschul, S. F., et al., “Gapped Blast and PSI-Blast: A New Generation of Protein Database Search Programs,” Nucleic Acids Research 25(17):3389-3402, Oxford University Press, United Kingdom (Sep. 1997).
[cited by applicant]
Ames, R. S., et al., “Conversion of Murine Fabs Isolated From a Combinatorial Phage Display Library to Full Length Immunoglobulins,” Journal of Immunological Methods 184(2):177-186, Elsevier, Netherlands (Aug. 1995).
[cited by applicant]
Baldridge, J. R., and Crane, R. T., “Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines,” Methods 19(1):103-107, Elsevier, Netherlands (Sep. 1999).
[cited by applicant]
Batzer, M. A., et al., “Enhanced evolutionary PCR using oligonucleotides with inosine at the 3′-terminus,” Nucleic Acids Res 19(18):5081, Oxford University Press, United Kingdom (Sep. 1991).
[cited by applicant]
Berge, S.M., et al., “Pharmaceutical Salts,” Journal of Pharmaceutical Sciences 66(1):1-19, Wiley, United States (Jan. 1977).
[cited by applicant]
Bieg, S., et al., “GAD65 and insulin B chain peptide (9-23) are not primary autoantigens in the type 1 diabetes syndrome of the BB rat,” Autoimmunity 31(1):15-24, Informa Healthcare, United Kingdom (Jan. 1999).
[cited by applicant]
Blank, C., et al., “Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy,” Cancer Immunol Immunother 54(4):307-314, Springer Scie…
[cited by applicant]
Blank, C., and Mackensen, A., “Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion,” Cancer Immunol Immunother 56(5):739-745, Springer Science+…
[cited by applicant]
Boder, E. T., and Wittrup, K. D., “Yeast surface display for directed evolution of protein expression, affinity, and stability,” Methods Enzymol 328:430-444, Elsevier, Netherlands (2000).
[cited by applicant]
Brennan, M., et al., “Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1 fragments,” Science 229(4708):81-83, American Association for the Advancement of Science, United State…
[cited by applicant]
Brinkmann, U., et al., “Phage Display of Disulfide-stabilized Fv Fragments,” Journal of Immunological Methods 182(1):41-50, Elsevier, Netherlands (May 1995).
[cited by applicant]
Brown, J. A., et al., “Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production,” J Immunol 170(3):1257-1266, American Association of Immunologists, United States (Feb…
[cited by applicant]
Burton, D. R. and Barbas, C. F. 3rd., “Human Antibodies From Combinatorial Libraries,” Advances in Immunology 57:191-280, Academic Press, United States (Aug. 1993).
[cited by applicant]
Canfield, S. M., and Morrison, S. L., “The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region,” J Exp Med 173(6):…
[cited by applicant]
Caron, P. C., et al., “Engineered humanized dimeric forms of IgG are more effective antibodies,” J Exp Med 176(4):1191-1195, Rockefeller University Press, United States (Oct. 1992).
[cited by applicant]
Cassol, S., et al., “Stability of dried blood spot specimens for detection of human immunodeficiency virus DNA by polymerase chain reaction,” J Clin Microbiol 30(12):3039-3042, American Society for Microbiology, United …
[cited by applicant]
Chasteen, L., et al., “Eliminating helper phage from phage display,” Nucleic Acids Res 34(21):e145, Oxford University Press, United Kingdom (Nov. 2006).
[cited by applicant]
Chen, D. S., and Mellman, I., “Oncology meets immunology: the cancer-immunity cycle,” Immunity 39(1):1-10, Cell Press, United States (Jul. 2013).
[cited by applicant]
Cheung, R. C., et al., “Epitope-specific antibody response to the surface antigen of duck hepatitis B virus in infected ducks,” Virology 176(2):546-552, BioMed Central Ltd, United States (Jun. 1990).
[cited by applicant]
Co, M. S., et al., “Genetically engineered deglycosylation of the variable domain increases the affinity of an anti-CD33 monoclonal antibody,” Mol Immunol 30(15):1361-1367, Pergamon Press, United Kingdom (Oct. 1993).
[cited by applicant]
Cornelis, P., “Expressing genes in different Escherichia coli compartments,” Curr Opin Biotechnol 11(5):450-454, Elsevier, Netherlands (Oct. 2000).
[cited by applicant]
Deans, R. J., et al., “Expression of an immunoglobulin heavy chain gene transfected into lymphocytes,” Proc Natl Acad Sci USA 81(5):1292-1296, National Academy of Science, United States (Mar. 1984).
[cited by applicant]
Di Niro, R., et al., “Characterizing monoclonal antibody epitopes by filtered gene fragment phage display,” Biochem J 388(Pt 3):889-894, Portland Press, United States (Jun. 2005).
[cited by applicant]
Dong, H., et al., “Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion,” Nat Med 8(8):793-800, Nature Publishing Group, United Kingdom (published online Jun. 2002, published in prin…
[cited by applicant]
Dong, H., and Chen, L., “B7-H1 pathway and its role in the evasion of tumor immunity,” J Mol Med (Berl) 81(5):281-287, Springer Science+Business Media, Germany (published online Apr. 2003, published in print May 2003).
[cited by applicant]
Duncan, A. R., and Winter, G., “The binding site for Clq on IgG,” Nature 332(6166):738-740, Nature Publishing Group, United Kingdom (Apr. 1988).
[cited by applicant]
Engberg, J., et al., “Phage-display libraries of murine and human antibody Fab fragments,” Methods Mol Biol 51:355-376, Humana Press, United States (1995).
[cited by applicant]
Eppstein, D. A., et al., “Biological activity of liposome-encapsulated murine interferon gamma is mediated by a cell membrane receptor,” Proc Natl Acad Sci USA 82(11):3688-3692, National Academy of Science, United State…
[cited by applicant]
Estep, P., et al., “High throughput solution-based measurement of antibody-antigen affinity and epitope binning,” mAbs 5(2):270-278, Landes Bioscience, United States (Mar.-Apr. 2013).
[cited by applicant]
Etz, H., et al., “Bacterial phage receptors, versatile tools for display of polypeptides on the cell surface,” J Bacteriol 183(23):6924-6935, American Society for Microbiology, United States (Dec. 2001).
[cited by applicant]
Fabbi, M., et al., “Dual Roles of IL-27 in Cancer Biology and Immunotherapy,” Mediators of Inflammation 2017:3958069, Hindawi Publishing Corporation, United States (Feb. 2017).
[cited by applicant]
Fergusson, J. R., et al., “CD161 defines a transcriptional and functional phenotype across distinct human T cell lineages,” Cell Rep 9(3):1075-1088, Cell Press, United States (published online Oct. 2014, published in pr…
[cited by applicant]
Freeman, G. J., et al., “Protect the killer: CTLs need defenses against the tumor,” Nat Med 8(8):787-789, Nature Publishing Group, United Kingdom (Aug. 2002).
[cited by applicant]
Fursov, N., et al., “Development and utilization of activated STAT3 detection assays for screening a library of secreted proteins,” Assay Drug Dev Technol 9(4):420-429, Mary Ann Liebert Inc., United States (published on…
[cited by applicant]
Gao, Q., et al., “Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma,” Clin Cancer Res 15(3):971-979, American Association for Cance…
[cited by applicant]
GenBank, “hPD-1 [
[cited by applicant]
GenBank, “interleukin-6 receptor subunit beta isoform 1 precursor [
[cited by applicant]
GenBank, “interleukin-27 receptor subunit alpha precursor [
[cited by applicant]
GenBank, “interleukin-27 subunit beta precursor [
[cited by applicant]
GenBank, “interleukin-27 subunit alpha precursor [
[cited by applicant]
GenBank, “stimulator of interferon genes protein isoform 2 [
[cited by applicant]
GenBank, “Programmed cell death 1 ligand 1,” Accession No. Q9NZQ7, accessed at https://www.ncbi.nlm.nih.gov/protein/Q9NZQ7 on Sep. 16, 2020, 8 pages.
[cited by applicant]
Ghebeh, H., et al., “The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors,” Neoplasia 8(3)…
[cited by applicant]
Grabherr, R., and Ernst, W., “The baculovirus expression system as a tool for generating diversity by viral surface display,” Combinatorial Chemistry & High Throughput Screening 4(2):185-192, Bentham Science Publishers …
[cited by applicant]
Gruber, M., et al., “Efficient tumor cell lysis mediated by a bispecific single chain antibody expressed in
[cited by applicant]
Gupta, R. K., and Siber, G. R., “Adjuvants for human vaccines—current status, problems and future prospects,” Vaccine 13(14):1263-1276, Elsevier, Netherlands (Oct. 1995).
[cited by applicant]
Hamanishi, J., et al., “Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer,” Proc Natl Acad Sci USA 104(9):3360-3365, National Academy of Science, U…
[cited by applicant]
Hanahan, D., and Weinberg, R. A., “Hallmarks of cancer: the next generation,” Cell 144(5):646-674, Cell Press, United States (Mar. 2011).
[cited by applicant]
Hanauske, A-R., et al., “Phase 1b dose escalation study of erlotinib in combination with infusional 5-Fluorouracil, leucovorin, and oxaliplatin in patients with advanced solid tumors,” Clin Cancer Res 13(2 Pt 1):523-531…
[cited by applicant]
Hanes, J., et al., “Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display,” Nat Biotechnol 18(12):1287-1292, Nature Publishing Group, United Kingdom (Dec. 2000).
[cited by applicant]
Harding, F. A., and Lonberg, N., “Class switching in human immunoglobulin transgenic mice,” Annals of the New York Academy of Sciences 764:536-546, Wiley-Blackwell on behalf of the New York Academy of Sciences, United S…
[cited by applicant]
Hetherington, S., et al., “Phase I dose escalation study to evaluate the safety and pharmacokinetic profile of tefibazumab in subjects with end-stage renal disease requiring hemodialysis,” Antimicrobial Agents and Chemo…
[cited by applicant]
Hino, R., et al., “Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma,” Cancer 116(7):1757-1766, John Wiley and Sons Inc., United States (Apr. 2010).
[cited by applicant]
Hisada, M., et al., “Potent antitumor activity of interleukin-27,” Cancer Res 64(3):1152-1156, American Association for Cancer Research Inc., United States (Feb. 2004).
[cited by applicant]
Holliger, P., et al., ““Diabodies”: small bivalent and bispecific antibody fragments,” Proc Natl Acad Sci USA 90(14):6444-6448, National Academy of Science, United States (Jul. 1993).
[cited by applicant]
Hoogenboom, H. R., “Designing and optimizing library selection strategies for generating high-affinity antibodies,” Trends Biotechnol 15(2):62-70, Cell Press, United States (Feb. 1997).
[cited by applicant]
Hou, J., and Zhan, H., “Expression of active thrombopoietin and identification of its key residues responsible for receptor binding,” Cytokine 10(5):319-330, Elsevier, Netherlands (May 1998).
[cited by applicant]
Houdebine, L. M., “Antibody manufacture in transgenic animals and comparisons with other systems,” Curr Opin Biotechnol 13(6):625-629, Elsevier, Netherlands (Dec. 2002).
[cited by applicant]
Hudson, P. J., and Kortt, A. A., “High avidity scFv multimers; diabodies and triabodies,” J Immunol Methods 231(1-2):177-189, Elsevier, Netherlands (Dec. 1999).
[cited by applicant]
Inman, B. A., et al., “PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression,” Cancer 109(8):1499-1505, John Wiley and Sons Inc., Unit…
[cited by applicant]
Irizarry, R. A., et al., “Exploration, normalization, and summaries of high density oligonucleotide array probe level data,” Biostatistics 4(2):249-264, Oxford University Press, United Kingdom (Apr. 2003).
[cited by applicant]
Ishida, Y., et al., “Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death,” The EMBO Journal 11(11):3887-3895, European Molecular Biology Organization Press, Germ…
[cited by applicant]
Isner, J. M., and Asahara, T., “Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization,” J Clin Invest 103(9):1231-1236, American Society for Clinical Investigation, United States (Ma…
[cited by applicant]
Iwai, Y., et al., “Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade,” Proc Natl Acad Sci USA 99(19):12293-12297, National Academy of Sciences, United St…
[cited by applicant]
Jankowski, M., et al., “Interleukin-27: biological properties and clinical application,” Arch Immunol Ther Exp (Warsz) 58(6):417-425, Springer Nature, Switzerland (published online Sep. 2010, published in print Dec. 201…
[cited by applicant]
Johnson, D. A., et al., “3-O-Desacyl monophosphoryl lipid A derivatives: synthesis and immunostimulant activities,” J Med Chem 42(22):4640-4649, American Chemical Society, United States (Nov. 1999).
[cited by applicant]
Kaszubska, W., et al., “Expression, purification, and characterization of human recombinant thrombopoietin in Chinese hamster ovary cells,” Protein Expr Purif 18(2):213-220, Elsevier, Netherlands (Mar. 2000).
[cited by applicant]
Kettleborough, C. A., et al., “Isolation of Tumor Cell-specific Single-chain Fv From Immunized Mice Using Phage-antibody Libraries and the Re-construction of Whole Antibodies From These Antibody Fragments,” European Jou…
[cited by applicant]
Kieke, M. C., et al., “Isolation of anti-T cell receptor scFv mutants by yeast surface display,” Protein Eng 10(11):1303-1310, Oxford University Press, United Kingdom (Nov. 1997).
[cited by applicant]
Kim, S., et al., “Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin,” Am J Pathol 156(4):1345-1362, Elsevier, Netherlands (Apr. 2000).
[cited by applicant]
Kim, S., et al., “Regulation of integrin alpha vbeta 3-mediated endothelial cell migration and angiogenesis by integrin alpha5beta1 and protein kinase A,” J Biol Chem 275(43):33920-33928, Elsevier, Netherlands (Oct. 200…
[cited by applicant]
Kinstler, O., et al., “Mono-N-terminal poly(ethylene glycol)-protein conjugates,” Adv Drug Deliv Rev 54(4):477-485, Elsevier, Netherlands (Jun. 2002).
[cited by applicant]
Kirkland, T. N., et al., “Analysis of the fine specificity and cross-reactivity of monoclonal anti-lipid A antibodies,” J Immunol 137(11):3614-3619, American Association of Immunologists, United States (Dec. 1986).
[cited by applicant]
Kitano, A., et al., “Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer,” ESMO Open 2(2):e000150, Elsevier, Netherlands (May 2017).
[cited by applicant]
Kleffel, S., et al., “Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth,” Cell 162(6):1242-1256, Cell Press, United States (Sep. 2015).
[cited by applicant]
Klemm, P., and Schembri, M. A., “Fimbrial surface display systems in bacteria: from vaccines to random libraries,” Microbiology (Reading) 146 (Pt 12):3025-3032, Microbiology Society, United States (Dec. 2000).
[cited by applicant]
Konishi, J., et al., “B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression,” Clin Cancer Res 10(15):5094-5100, American Association for …
[cited by applicant]
Kostelny, S. A., et al., “Formation of a bispecific antibody by the use of leucine zippers,” J Immunol 148(5):1547-1553, American Association of Immunologists, United States (Mar. 1992).
[cited by applicant]
Langer, R., “Biocompatibility of polymeric delivery systems for macromolecules,” Journal of Biomedical Materials Research 15(2):267-277, Heterocorporation, United States (Mar. 1981).
[cited by applicant]
Langer, R., “Controlled release of macromolecules,” Chem. Tech 12(2):98-105, American Chemical Society, United States (Feb. 1982).
[cited by applicant]
Lee, L. S., et al., “Prolonged circulating lives of single-chain Fv proteins conjugated with polyethylene glycol: a comparison of conjugation chemistries and compounds,” Bioconjug Chem 10(6):973-981, American Chemical S…
[cited by applicant]
Liu, L., et al., “IL-27-mediated activation of natural killer cells and inflammation produced antitumour effects for human oesophageal carcinoma cells,” Scandinavian Journal of Immunology 68(1):22-29, Wiley-Blackwell Pu…
[cited by applicant]
Lodmell, D. L., et al., “DNA vaccination of mice against rabies virus: effects of the route of vaccination and the adjuvant monophosphoryl lipid A (MPL),” Vaccine 18(11-12):1059-1066, Elsevier, Netherlands (Jan. 2000).
[cited by applicant]
Lonberg, N., et al., “Antigen-specific human antibodies from mice comprising four distinct genetic modifications,” Nature 368(6474):856-859, Nature Publishing Group, United Kingdom (Apr. 1994).
[cited by applicant]
Lonberg, N., “Transgenic approaches to human monoclonal antibodies,” in Handbook of Experimental Pharmacology, the Pharmacology of Monoclonal Antibodies, vol. 113, pp. 49-101, Rosenberg, M., et al., eds., Springer-Verla…
[cited by applicant]
Lonberg, N., and Huszar, D., “Human antibodies from transgenic mice,” International Reviews of Immunology 13(1):65-93, Informa Healthcare, United Kingdom (Jan. 1995).
[cited by applicant]
Lonberg, N., “Human antibodies from transgenic animals,” Nat Biotechnol 23(9):1117-1125, Nature Publishing Group, United Kingdom (Sep. 2005).
[cited by applicant]
Lusky, M., and Botchan, M., “Inhibition of SV40 replication in simian cells by specific pBR322 DNA sequences,” Nature 293(5827):79-81, Nature Publishing Group, United Kingdom (Sep. 1981).
[cited by applicant]
Merz, D. C., et al., “Generating a phage display antibody library against an identified neuron,” J Neurosci Methods 62(1-2):213-219, Elsevier, Netherlands (Nov. 1995).
[cited by applicant]
Milstein, C., and Cuello, A. C., “Hybrid hybridomas and their use in immunohistochemistry,” Nature 305(5934):537-540, Nature Publishing Group, United Kingdom (Oct. 1983).
[cited by applicant]
Moldenhauer, G., et al., “Identity of HML-1 antigen on intestinal intraepithelial T cells and of B-ly7 antigen on hairy cell leukaemia,” Scandinavian Journal of Immunology 32(2):77-82, Blackwell Scientific Publications,…
[cited by applicant]
Morel, G. A., et al., “Monoclonal antibodies to bovine serum albumin: affinity and specificity determinations,” Molecular Immunology 25(1):7-15, Pergamon Press, United Kingdom (Jan. 1988).
[cited by applicant]
Motz, G. T., and Coukos, G., “Deciphering and reversing tumor immune suppression,” Immunity 39(1):61-73, Cell Press, United States (Jul. 2013).
[cited by applicant]
Mueller, J. P., et al., “Humanized porcine VCAM-specific monoclonal antibodies with chimeric IgG2/G4 constant regions block human leukocyte binding to porcine endothelial cells,” Mol Immunol 34(6):441-452, Elsevier, Net…
[cited by applicant]
Mulligan, R. C., and Berg, P., “Selection for animal cells that express the
[cited by applicant]
Muyldermans, S., et al., “Recognition of antigens by single-domain antibody fragments: the superfluous luxury of paired domains,” Trends Biochem Sci 26(4):230-235, Cell Press, United States (Apr. 2001).
[cited by applicant]
Myers, E. W., and Miller, W., “Optimal alignments in linear space,” Comput Appl Biosci 4(1):11-17, IRL Press Ltd., United Kingdom (Mar. 1988).
[cited by applicant]
Nakanishi, J., et al., “Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers,” Cancer Immunol Immunother 56(8):1173-1182, Springer Science+Bus…
[cited by applicant]
Needleman, S.B., and Wunsch, C. D., “A general method applicable to the search for similarities in the amino acid sequence of two proteins,” Journal of Molecular Biology 48(3):443-453, American Society for Biochemistry …
[cited by applicant]
Nuttall, S. D., et al., “Immunoglobulin VH domains and beyond: design and selection of single-domain binding and targeting reagents,” Current Pharmaceutical Biotechnology 1(3):253-263, Bentham Science Publishers B.V., U…
[cited by applicant]
Ohigashi, Y., et al., “Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer,” Clin Cancer Res 11(8):2947-2953, American Association for Cancer Resear…
[cited by applicant]
Ohtsuka, E., et al., “An alternative approach to deoxyoligonucleotides as hybridization probes by insertion of deoxyinosine at ambiguous codon positions,” J Biol Chem 260(5):2605-2608, Elsevier, Netherlands (Mar. 1985).
[cited by applicant]
Paolino, M., and Penninger, J. M., “The Role of TAM Family Receptors in Immune Cell Function: Implications for Cancer Therapy,” Cancers 8(10):97, MDPI, Switzerland (Oct. 2016).
[cited by applicant]
Pavisic, R., et al., “Recombinant human granulocyte colony stimulating factor pre-screening and screening of stabilizing carbohydrates and polyols,” Int J Pharm 387(1-2):110-119, Elsevier, Netherlands (published online …
[cited by applicant]
Pearson, W.R., and Lipman, D.J., “Improved tools for biological sequence comparison,” Proceedings of the National Academy of Sciences 85(8):2444-2448, National Academy of Sciences, United States (Apr. 1988).
[cited by applicant]
Pereboev, A., et al., “Phage display of adenovirus type 5 fiber knob as a tool for specific ligand selection and validation,” J Virol 75(15):7107-7113, American Society for Microbiology, United States (Aug. 2001).
[cited by applicant]
Persic, L., et al., “An Integrated Vector System for the Eukaryotic Expression of Antibodies or Their Fragments After Selection From Phage Display Libraries,” Gene 187(1):9-18, Elsevier/North-Holland, Netherlands (Mar. …
[cited by applicant]
Poljak, R. J., “Production and structure of diabodies,” Structure 2(12):1121-1123, Cell Press, United States (Dec. 1994).
[cited by applicant]
Pollock, D. P., et al., “Transgenic milk as a method for the production of recombinant antibodies,” J Immunol Methods 231(1-2):147-157, Elsevier, Netherlands (Dec. 1999).
[cited by applicant]
Riechmann, L. and Muyldermans, S., “Single Domain Antibodies: Comparison of Camel VH and Camelised Human VH Domains,” Journal of Immunological Methods 231(1-2):25-38, Elsevier, Netherlands (Dec. 1999).
[cited by applicant]
Roberts, M. J., et al., “Chemistry for peptide and protein PEGylation,” Adv Drug Deliv Rev 54(4):459-476, Elsevier, Netherlands (Jun. 2002).
[cited by applicant]
Rogers, B. E., et al., “Localization of iodine-125-mIP-Des-Met14-bombesin (7-13)NH2 in ovarian carcinoma induced to express the gastrin releasing peptide receptor by adenoviral vector-mediated gene transfer,” The Journa…
[cited by applicant]
Rondon, I. J., and Marasco, W. A., “Intracellular antibodies (intrabodies) for gene therapy of infectious diseases,” Annual Review of Microbiology 51:257-283, Annual Reviews Inc., United States (1997).
[cited by applicant]
Rossolini, G. M., et al., “Use of deoxyinosine-containing primers vs degenerate primers for polymerase chain reaction based on ambiguous sequence information,” Mol Cell Probes 8(2):91-98, Elsevier, Netherlands (Apr. 199…
[cited by applicant]
Sarver, N., et al., “Transformation and replication in mouse cells of a bovine papillomavirus—pML2 plasmid vector that can be rescued in bacteria,” Proc Natl Acad Sci USA 79(23):7147-7151, National Academy of Sciences, …
[cited by applicant]
Sauer, K. A., et al., “Immunosurveillance of lung melanoma metastasis in EBI-3-deficient mice mediated by CD8+ T cells,” J Immunol 181(9):6148-6157, American Association of Immunologists, United States (Nov. 2008).
[cited by applicant]
Schaffitzel, C., et al., “Ribosome display: an in vitro method for selection and evolution of antibodies from libraries,” J Immunol Methods 231(1-2):119-135, Elsever, Netherlands (Dec. 1999).
[cited by applicant]
Schoonbroodt, S., et al., “Oligonucleotide-assisted cleavage and ligation: a novel directional DNA cloning technology to capture cDNAs. Application in the construction of a human immune antibody phage-display library,” …
[cited by applicant]
Shalaby, M. R., et al., “Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene,” J Exp Med 175(1):217-225, Rockefeller University Press,…
[cited by applicant]
Shi, L., et al., “De novo selection of high-affinity antibodies from synthetic fab libraries displayed on phage as pIX fusion proteins,” J Mol Biol 397(2):385-396, Elsevier, Netherlands (published online Jan. 2010, publ…
[cited by applicant]
Shimauchi, T., et al., “Augmented expression of programmed death-1 in both neoplastic and non-neoplastic CD4+ T-cells in adult T-cell leukemia/lymphoma,” Int J Cancer 121(12):2585-2590, John Wiley & Sons on behalf of th…
[cited by applicant]
Shimizu, M., et al., “Antiangiogenic and antitumor activities of IL-27,” J Immunol 176(12):7317-7324, American Association of Immunologists, United States (Jun. 2006).
[cited by applicant]
Shiraishi, M., et al., “Short-step chemical synthesis of DNA by use of MMTrS group for protection of 5′-hydroxyl group,” Nucleic Acids Symposium Series (Oxf) 51:129-130, Oxford University Press, United Kingdom (Nov. 200…
[cited by applicant]
Shopes, B., “A genetically engineered human IgG mutant with enhanced cytolytic activity,” J Immunol 148(9):2918-2922, American Association of Immunologists, United States (May 1992).
[cited by applicant]
Sidman, K. R., et al., “Controlled release of macromolecules and pharmaceuticals from synthetic polypeptides based on glutamic acid,” Biopolymers 22(1):547-556, John Wiley and Sons Inc., United States (Jan. 1983).
[cited by applicant]
Siegel, R. W., et al., “High efficiency recovery and epitope-specific sorting of an scFv yeast display library,” J Immunol Methods 286(1-2):141-153, Elsevier, Netherlands (Mar. 2004).
[cited by applicant]
Smith, T.F., and Waterman, M.S., “Comparison of biosequences,” Advances in Applied Mathematics 2(4):482-498, Academic Press Inc., United States (1981).
[cited by applicant]
Songsivilai, S. and Lachmann, P.J., “Bispecific Antibody: A Tool for Diagnosis and Treatment of Disease,” Clinical and Experimental Immunology 79(3):315-321, Blackwell Scientific Publications, United Kingdom (Mar. 1990).
[cited by applicant]
Southern, P. J., and Berg, P., “Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter,” Journal of Applied Genetics 1(4):327-341, Springer, Germ…
[cited by applicant]
Stahli, C., et al., “Distinction of epitopes by monoclonal antibodies,” Methods in Enzymology 92:242-253, Academic Press, United States (1983).
[cited by applicant]
Suresh, M. R., et al., “Bispecific monoclonal antibodies from hybrid hybridomas,” Methods in Enzymology 121:210-228, Academic Press, United States (1986).
[cited by applicant]
Takahashi, T., et al., “Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization,” Nat Med 5(4):434-438, Nature Publishing Group, United Kingdom (Apr. 1999).
[cited by applicant]
Thompson, R. H., and Kwon, E. D., “Significance of B7-H1 overexpression in kidney cancer,” Clin Genitourin Cancer 5(3):206-211, Elsevier, Netherlands (Dec. 2006).
[cited by applicant]
Tochizawa, S., et al., “A novel modification of a flow cytometric assay of phosphorylated STATI in whole blood lymphocytes for rapid detection of interferon-alpha signal in vivo,” J Immunol Methods 313(1-2):29-37, Elsev…
[cited by applicant]
Todorovska, A., et al., “Design and application of diabodies, triabodies and tetrabodies for cancer targeting,” J Immunol Methods 248(1-2):47-66, Elsevier, Netherlands (Feb. 2001).
[cited by applicant]
Tutt, A., et al., “Trispecific F(ab')3 derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells,” J Immunol 147(1):60-69, American Association of Immu…
[cited by applicant]
UniProtKB, T-cell immunoreceptor with Ig and ITIM domains, Accession No. Q495A1, accessed at https://www.uniprot.org/uniprot/Q495A1, accessed on Aug. 23, 2021, 12 pages.
[cited by applicant]
Van Gurp, E., et al., “Phase 1 dose-escalation study of CP-690 550 in stable renal allograft recipients: preliminary findings of safety, tolerability, effects on lymphocyte subsets and pharmacokinetics,” American Journa…
[cited by applicant]
Van Kuik-Romeijn, P., et al., “Expression of a functional mouse-human chimeric anti-CD19 antibody in the milk of transgenic mice,” Transgenic Research 9(2):155-159, Springer, Switzerland (Apr. 2000).
[cited by applicant]
Varner, J. A., et al., “Inhibition of angiogenesis and tumor growth by murine 7E3, the parent antibody of c7E3 Fab (abciximab; ReoPro),” Angiogenesis 3(1):53-60, Springer, Netherlands (1999).
[cited by applicant]
Wigler, M., et al., “Transformation of mammalian cells with genes from procaryotes and eucaryotes,” Cell 16(4):777-785, Cell Press, United States (Apr. 1979).
[cited by applicant]
Wright, A., et al., “Antibody variable region glycosylation: position effects on antigen binding and carbohydrate structure,” EMBO J 10(10):2717-2723, European Molecular Biology Organization Press, Germany (Oct. 1991).
[cited by applicant]
Wu, C., et al., “Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin,” Nat Biotechnol 25(11):1290-1297, Nature Publishing Group, United Kingdom (published online Oct. 2007, publ…
[cited by applicant]
Xu, Y., et al., “Addressing polyspecificity of antibodies selected from an in vitro yeast presentation system: a FACS-based, high-throughput selection and analytical tool,” Protein Eng Des Sel 26(10):663-670, Oxford Uni…
[cited by applicant]
Yang, W., et al., “PD-L1: PD-1 interaction contributes to the functional suppression of T-cell responses to human uveal melanoma cells in vitro,” Investigative Ophthalmology & Visual Science 49(6):2518-2525, Association…
[cited by applicant]
Yeung, Y. A., and Wittrup, K. D., “Quantitative screening of yeast surface-displayed polypeptide libraries by magnetic bead capture,” Biotechnology Progress 18(2):212-220, Wiley-Blackwell, United States (Mar.-Apr. 2002).
[cited by applicant]
Zapata, G., et al., “Engineering linear F(ab')2 fragments for efficient production in
[cited by applicant]
Zhan, M-M., et al., “From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1/PD-L1 pathway,” Drug Discov Today 21(6):1027-1036, Elsevier, Netherlands (published online Apr. 2016, …
[cited by applicant]
Michael, S. I., et al., “Addition of a short peptide ligand to the adenovirus fiber protein,” Gene Therapy 2(9):660-668, Nature Publishing Group, United Kingdom (1995).
[cited by applicant]
Bender et al., “Interleukin-27 Displays Interferon-y-Like Functions in Human Hepatoma Cells and Hepatocytes,” Hepatology, 50:585-591 (2009).
[cited by applicant]
Bosmann et al., “Modulation of inflammation by interleukin-27,” Journal of Leukocyte Biology, 94: 1159-1165 (2013).
[cited by applicant]
Devergne et al., “A Novel Interleukin-12 p40-Related Protein Induced by Latent Epstein-Barr Virus Infection in B Lymphocytes,” Journal of Virology, 70(2): 1143-1153 (1996).
[cited by applicant]
Devergne et al., “Expression of Epstein-Barr Virus-Induced Gene 3, an Interleukin-12 p40-Related Molecule, throughout Human Pregnancy,” American Journal of Pathology, 159(5):1763-1776 (2001).
[cited by applicant]
Diakowska et al., “Concentration of Serum Interleukin-27 Increase in Patients with Lymph Node Metastatic Gastroesophageal Cancer,” Adv Clin Exp Med, 22(5):683-691 (2013).
[cited by applicant]
Dietrich et al., “A Soluble Form of IL-27Ra is a Natural IL-27 Antagonist,” The Journal of Immunology, 192:5382-5389 (2014).
[cited by applicant]
Ganin et al., “Expression of IL-27 by Tumor Cells in InvasCutaneous and Metastatic Melanomas,” PLOS ONE, 8 (1 0): e75694 (2013).
[cited by applicant]
Hunter et al., “Interleukin-27: Balancing Protective and Pathological Immunity,” Immunity, 37:960-969 (2012).
[cited by applicant]
Intemational Search Report and Written Opinion in corresponding PCT Application No. PCT/US19/23625 dated Aug. 7, 2019, 23 pages.
[cited by applicant]
International Search Report and Written Opinion in corresponding PCT Application No. PCT/US19/53036 dated Feb. 14, 2020, 18 pages.
[cited by applicant]
Larousserie et al., “Analysis of Interleukin-27 (EBI3/p28) Expression in Epstein-Barr Virus- and Human T-Cell Leukemia Virus Type 1-Associated Lymphomas,” American Journal of Pathology, 166(4):1217-1228 (2005).
[cited by applicant]
Nishina et al., “Identification of Epstein-Barr Virus-Induced Gene 3 as a Novel Serum and Tissue Biomarker and a Therapeutic Target for Lung Cancer,” Clin Cancer Res, 17(19):6272-6286 (2011 ).
[cited by applicant]
Petretto et al., “Proteomic analysis uncovers common effects of IFN-y and IL-27 on the HLA class I antigen presentation machinery in human cancer cells,” Oncotarget, 7(45):72518-72536 (2016).
[cited by applicant]
Pflanz et al., “WSX-1 and Glycoprotein 130 Constitute a Signal-Transducing Receptor for I L-27,” The Journal of Immunology, 172:2225-2231 (2004).
[cited by applicant]
Pu et al., “Association between polymorphisms in IL27 gene and renal cell carcinoma,” Biomarkers, 20(3):202-205 (2015).
[cited by applicant]
Rousseau et al., “IL-27 structural analysis demonstrates similarities with ciliary neurotrophic factor (CNTF) and leads to the identification of antagonistic variants,” PNAS, 107(45): 19420-19425 (2010).
[cited by applicant]
Song et al., “Downregulation of Epstein-Barr virus-induced gene 3 is associated with poor prognosis of hepatocellular carcinoma after curative resection,” Oncology Letters, 15:7751-7759 (2018).
[cited by applicant]
Tang et al., “Associations of IL-27 Polymorphisms and Serum IL-27p28 Levels With Osteosarcoma Risk,” Medicine, 93(1 0):e56 (2014 ).
[cited by applicant]
Vander Heiden et al., Dysregulation of B Cell Repertoire Formation in Myasthenia Gravis Patients Revealed Through Deep Sequencing, Journal of Immunology, vol. 198, No. 4, Jan. 13, 2017, pp. 1460-1473.
[cited by applicant]
Yang e.t al., “Cell Origins and Diagnostic Accuracy of Interleukin 27 in Pleural Effusions,” PLOS ONE, 7(7):e40450 (2012).
[cited by applicant]
Yoshida et al., “The Immunobiology of Interleukin-27,” Annu. Rev. Immunol, 33:417-443 (2015).
[cited by applicant]
Zhang et al., “Association of 3 Common Polymorphisms of IL-27 Gene with Susceptibility to Cancer in Chinese: Evidence From an Updated Meta-Analysis of 27 Studies,” Med Sci Monit, 21 :2505-2513 (2015).
[cited by applicant]
Zhou et al., “Polymorphisms and plasma levels of IL-27: impact on genetic susceptibility and clinical outcome of bladder cancer,” BMC Cancer, 15:433 (2015).
[cited by applicant]
Karakhanova, S. et al. “IL-27 renders DC immunosuppressive by induction of B7-H1”, Journal of Leukocyte Biology; vol. 89, Issue 6, Jun. 2011, pp. 837-845; doi: 10.1189/jlb.1209788.
[cited by applicant]
Sprokholt, J. K. et al. “RIG-I-like receptor activation by dengue virus drives follicular T helper cell formation and antibody production”, PLoS Pathog, 2017, vol. 13, No. 11, article No. e1006738, doi: 10.1371/journal.…
[cited by applicant]
Haman Ish I, J. et al.; “PD-1 /Pd-L 1 blockade in cancer treatment: perspectives and issues”; International Journal of Clinical Oncology, Feb. 22, 2016, vol. 21, pp. 462-473.
[cited by applicant]
Australian Examination Report No. 1 for Australian Application No. 201929324 dated Jul. 30, 2025 (15 pages).
[cited by applicant]